A Bitter Pill for India’s Poor: The Rising Cost of Life-Saving Medicines

Abhijit Roy

At a time when the rising cost of living is making survival difficult, the National Pharmaceutical Pricing Authority’s (NPPA) decision to allow price hikes for certain life-saving medicines is akin to adding insult to injury for the vulnerable sections of society. The price increases sanctioned by the NPPA include a 50 percent hike for certain cancer drugs, anti-tetanus serum, and vaccines for children. This decision undoubtedly highlights inconsistencies in public health policy. There is no doubt that keeping essential medicines affordable is crucial in a country like India, where many families bear the cost of medical treatment out of their own pockets. At the same time, ensuring the ready availability of life-saving medicines in the market is equally important. While the price hikes for certain medicines and vaccines might be justified by citing supply chain disruptions caused by the US-Iran conflict, concerns regarding the economic disparity between the rich and the poor within the healthcare system remain entirely valid. In fact, the NPPA has cited drug shortages and rising production costs as the reasons for the price increases. The argument put forward is that if pharmaceutical companies are unable to recover their production costs, they might stop supplying these medicines to the open market. Nevertheless, the constraints and economic circumstances of the poor must also be taken into consideration.

Nevertheless, despite the arguments put forward in this regard, one cannot overlook the fact that millions of people in this country struggle to afford basic healthcare services. Undoubtedly, a fifty percent hike in the prices of cancer treatments and medicines that protect children from diseases can plunge economically vulnerable families into a deep financial crisis. For patients, treatment costs encompass not only medicines but also diagnostic tests, travel from remote areas to major hospitals, hospitalization expenses, and the loss of income incurred during the treatment period. In such a scenario, the additional burden of rising medicine prices could force them to make agonizing choices between undergoing treatment and mere survival. The solution lies not in choosing between affordability and availability, but in developing a system that ensures both. The government needs to make the medicine procurement process for public hospitals transparent and robust. It must ensure the uninterrupted supply of medicines through these hospitals. Furthermore, essential medicines should be included in health insurance schemes so that poor patients can be shielded from sudden price hikes through targeted subsidies. Additionally, policies regarding medicine prices should be reviewed periodically to accurately assess the actual increase in production costs.